Cubist continues to rally

|By:, SA News Editor

Shares of Cubist Pharmaceuticals (CBST +4.9%) are up handsomely again today, adding to gains posted Wednesday following the company's acquisitions of Trius and Optimer. (previous coverage)

Aegis Capital upgrades CBST to Buy.

Jefferies ups the price target on CBST to $70 from $64. Acquisitions should increase earnings in FY14, 15, and 16 by 7%, 13%, and 17% respectively, analyst Eun Yang says.